ALE.P02
- Generic Name
- ALE.P02
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Phase 1
Recruiting
- Conditions
- Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 170
- Registration Number
- NCT06747585
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸NEXT Oncology Virginia, Fairfax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath